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S U M M A R Y
Objective: To examine the association between hepatitis B virus (HBV) infection and liver ﬁbrosis in HIV-
infected patients in Zambia and Switzerland.
Methods: HIV-infected adults starting antiretroviral therapy in two clinics in Zambia and Switzerland
were included. Liver ﬁbrosis was evaluated using the aspartate aminotransferase-to-platelet-ratio index
(APRI), with a ratio >1.5 deﬁning signiﬁcant ﬁbrosis and a ratio >2.0 indicating cirrhosis. The association
between hepatitis B surface antigen (HBsAg) positivity, HBV replication, and liver ﬁbrosis was examined
using logistic regression.
Results: In Zambia, 96 (13.0%) of 739 patients were HBsAg-positive compared to 93 (4.5%) of 2058 in
Switzerland. HBsAg-positive patients were more likely to have signiﬁcant liver ﬁbrosis than HBsAg-
negative ones: the adjusted odds ratio (aOR) was 3.25 (95% conﬁdence interval (CI) 1.44–7.33) in Zambia
and 2.50 (95% CI 1.19–5.25) in Switzerland. Patients with a high HBV viral load (20 000 IU/ml) were
more likely to have signiﬁcant liver ﬁbrosis compared to HBsAg-negative patients or patients with an
undetectable viral load: aOR 3.85 (95% CI 1.29–11.44) in Zambia and 4.20 (95% CI 1.64–10.76) in
Switzerland. In both settings, male sex was a strong risk factor for signiﬁcant liver ﬁbrosis.
Conclusions: Despite the differences in HBV natural history between Sub-Saharan Africa and Europe, the
degree of liver ﬁbrosis and the association with important risk factors were similar.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The increasing availability of antiretroviral therapy (ART) for
HIV-infected individuals has led to a dramatic reduction in AIDS-
related mortality and to the emergence of liver-related complica-
tions of hepatitis B virus (HBV) and hepatitis C virus (HCV)ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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the single most important cause of liver cirrhosis and causes over
50% of cases of hepatocellular carcinoma (HCC).2 HIV infection
accelerates the progression of HBV-related liver ﬁbrosis, especially
if cellular immunity is impaired or in the absence of adequate
treatment of HBV infection.3 A recent study from Nigeria showed
that HIV/HBV co-infected individuals were ﬁve times more likely
to have advanced liver ﬁbrosis compared to HIV monoinfected
people.4
Although the mechanisms of HBV-related ﬁbrogenesis are not
fully understood, recent results from prospective cohorts in
Europe, North America, and Asia have provided new insights into
its main determinants.5 Several host and viral risk factors,
including male sex, old age, high HBV viral load, and speciﬁc
HBV genotypes, have been associated with the development of
liver ﬁbrosis, cirrhosis, and HCC. However, data from Sub-Saharan
Africa (SSA), where HBV prevalence is highest, are scarce. In SSA,
most infections occur during early childhood, in contrast to
Western Europe, where the majority of patients are infected as
adults.6 As HBV transmission patterns and the duration of infection
may inﬂuence the development of liver ﬁbrosis and HCC, HIV/HBV
co-infected patients in SSA could be at high risk of developing early
liver disease.5 In addition, the burden of HBV-related complica-
tions might be increased by the presence of concurrent infections
such as hepatitis delta virus (HDV) and schistosomal infections, as
well as environmental exposures such as aﬂatoxins.7–9
Several non-invasive measurements have been used for the
staging of liver ﬁbrosis in HIV-infected and HIV/HBV co-infected
individuals.10,11 The aspartate aminotransferase-to-platelet ratio
index (APRI), which has been associated with mortality in SSA,12 is
recommended by the World Health Organization (WHO) for the
assessment of the presence of liver ﬁbrosis where liver biopsy is
unavailable.13,14 In this study, the stages of liver ﬁbrosis were
compared between HIV-infected and HIV/HBV co-infected indi-
viduals in cohorts from Zambia and Switzerland using the APRI.
This provided a unique opportunity to assess the impact of HBV
transmission patterns on the development of liver ﬁbrosis and to
evaluate its most important clinical and biological determinants in
two distinct epidemiological contexts.
2. Methods
2.1. HIV cohorts in Zambia and Switzerland
Analyses were based on two HIV cohorts in Zambia and
Switzerland.
HIV-infected adults receiving ART in two urban clinics in
Lusaka, where care was provided to the standard of the national
program, were included.15 Routine baseline examinations
included a medical history, physical examination, and laborato-
ry measurements (CD4 cell count, full blood count, serum
creatinine, and aminotransferases). In addition, all patients were
tested for hepatitis B surface antigen (HBsAg) and anti-HCV
antibodies, and HBV sequencing as well as viral load measure-
ments were performed in HBsAg-positive individuals within the
framework of a sub-study of the IeDEA-SA (International
epidemiological Databases to Evaluate AIDS in Southern
Africa).16 All data were entered into an electronic database
for clinical care, monitoring, evaluation, and reporting purposes.
Written informed consent was obtained from all patients. The
Biomedical Research Ethics Committee of the University of
Zambia School of Medicine and the Institutional Review Board of
the University of North Carolina at Chapel Hill, USA, approved
the study.
Established in 1988, the Swiss HIV Cohort Study (SHCS, http://
www.shcs.ch) is a prospective nationwide cohort study withongoing enrolment of HIV-infected adults. It covers approximately
50% of the cumulative number of HIV infections reported to the
Swiss public health authorities and 75% of patients receiving ART in
Switzerland.17 Detailed information on demographics, mode of
HIV acquisition, risk behaviour, clinical events, co-infections, and
treatment is collected using a standard protocol at registration and
then at 6-monthly intervals. All participants are screened for HBV
infection at study entry. Positive HBsAg tests are conﬁrmed with an
HBV DNA measurement. The local ethics committees at all
participating study sites approved the study, and written consent
was obtained from all participants.
2.2. Inclusion criteria and deﬁnitions
All adults with measurements of HBsAg, alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), and platelets
before ART initiation were included. Patients who tested positive
for anti-HCV antibodies were excluded. Liver ﬁbrosis was
evaluated using the APRI, a non-invasive score originally validated
in HIV/HCV co-infected patients and previously used in studies of
HIV-infected and HIV/HBV co-infected individuals.11,12,18,19 The
following cut-offs were used, as recommended by the WHO:
0.5 and 1.5 to rule-out and conﬁrm signiﬁcant ﬁbrosis (equivalent
to METAVIR stages 2 and above), respectively, and 1.0 and 2.0 to
rule-out and conﬁrm cirrhosis (METAVIR stage 4), respectively.13
Grade 1 ALT elevation (1.25–2.5 times the upper limit of normal
(ULN)) was deﬁned according to Division of AIDS criteria.20
In the SHCS, alcohol intake has been assessed routinely at 6-
month intervals since 2005.21 In Zambia, alcohol consumption was
investigated in all patients at ART initiation using the AUDIT-C
tool.22 At-risk alcohol intake was deﬁned according to the National
Institute on Alcoholism and Alcohol Abuse (NIAAA) as an average
daily consumption above one standard drink (10 g of pure alcohol)
for women and above two standard drinks for men.
2.3. Laboratory analyses
HBsAg-positivity was assessed using the point-of-care Deter-
mine rapid test (Alere, Yavne, Israel) in Zambia and recommended
commercial serological assays in Switzerland. HCV infection was
evaluated using the anti-HCV antibody rapid test OraQuick
(OraSure Technologies Inc., Bethlehem, PA, USA) in Zambia and
the ARCHITECT anti-HCV assay (Abbott Diagnostics, Wiesbaden,
Germany) in Switzerland. HBV DNA testing was performed using
real-time PCR (Roche COBAS AmpliPrep/Taqman HBV test) in both
countries. All measurements were performed before the initiation
of ART, or within the ﬁrst month of ART.
2.4. Statistical analyses
Differences in baseline demographic characteristics and clinical
and liver-related parameters at ART initiation between HBsAg-
positive and HBsAg-negative individuals in the two cohorts were
tested using the Chi-square test and Mann–Whitney test. Logistic
regression was used to evaluate the association between HBsAg
positivity and signiﬁcant liver ﬁbrosis (APRI 1.5). The following
potential confounders were adjusted for in multivariable models:
sex, age (below vs. above 40 years), country (Zambia vs.
Switzerland), CD4 cell count (below vs. above 200 cells/ml),
clinical stage of HIV disease (advanced vs. not advanced, with
advanced deﬁned as WHO stages III or IV for Zambia and CDC stage
C for Switzerland), and alcohol consumption (at-risk consumption
vs. no or not-at-risk consumption). The logistic regression analysis
was repeated after stratiﬁcation by country. As some of the
comparisons of HBV-related determinants between patients from
Zambia and Switzerland might have been biased by the presence of
Figure 1. Proportion of patients with signiﬁcant ﬁbrosis (A) and cirrhosis (B), by
country and HBV status.
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repeated after excluding the latter.
To evaluate the role of HBV replication on the degree of liver
ﬁbrosis, the logistic regression analyses were repeated including
levels of HBV replication in three categories: (1) no HBV infection
or HBV infection with an HBV viral load <20 IU/ml, (2) HBV viral
load between 20 and 19 999 IU/ml, and (3) HBV viral load
20 000 IU/ml. The association between HBV viral load and
signiﬁcant ﬁbrosis and cirrhosis was further explored by repeating
the analyses after excluding HIV/HBV co-infected patients with
high viral loads but normal aminotransferases (as a proxy for the
immune-tolerant proﬁle). All statistical analyses were performed
using Stata 12.0 (Stata Corp, College Station, TX, USA).
3. Results
3.1. Demographic and clinical characteristics
In Zambia, 96 (13.0%) of 739 HIV-infected patients were HBsAg-
positive compared to 93 (4.5%) of 2058 patients in Switzerland
(p < 0.001). The age and sex distribution were similar in HBsAg-
positive and HBsAg-negative patients (Table 1). The prevalence of
advanced disease and median CD4 counts were also similar in
HBsAg-positive and HBsAg-negative patients in the two cohorts,
but patients in Zambia had more advanced disease and lower CD4
cell counts. The prevalence of at-risk alcohol use was somewhat
higher in HBsAg-positive patients than HBsAg-negative patients in
both Zambia and Switzerland, but the differences failed to reach
statistical signiﬁcance (p > 0.20). At-risk alcohol intake was more
common in Zambia than in Switzerland (24.9% vs. 9.9%, p < 0.001).
In Switzerland, 26.9% of HIV/HBV co-infected individuals were of
African origin, whereas this group represented only 15.6% of
HBsAg-negative patients.
3.2. Liver-related parameters
In both countries, HIV/HBV co-infected individuals were
approximately twice as likely to have a grade 1 ALT elevation or
higher as HIV monoinfected patients (Table 1). As shown in
Figure 1, the proportion of patients with signiﬁcant liver ﬁbrosis
(APRI >1.5) was higher in HIV/HBV co-infected patients than in
HIV monoinfected patients (10.4% vs. 3.6% in Zambia, 14.0% vs.
4.4% in Switzerland). The proportion of individuals with liver
cirrhosis was below 3% in all groups except in HIV/HBV co-infectedTable 1
Baseline characteristics of the patients, by cohort
Zambia 
HIV
(n = 643)
HIV/HBV
(n = 96)
General characteristics
Female (%) 346 (53.8) 42 (43.8) 
African origin (%) 643 (100) 96 (100) 
Age, years, median (IQR) 34 (29–41) 34 (29–39) 
At-risk alcohol intake (%) 155 (24.1) 29 (30.2) 
Advanced HIV disease (%) 288 (45.4) 38 (40.0) 
CD4, cells/ml, median (IQR) 226 (121–330) 233 (114–361) 
Creatinine, mmol/l, median (IQR) 80 (70–92) 79 (70–91) 
Platelets, 109/l, median (IQR) 250 (197–316) 246 (190–303) 
Liver-related characteristics
Grade 1 ALT elevation or above (%) 49 (7.6) 14 (14.6) 
APRI, median (IQR) 0.36 (0.26–0.53) 0.44 (0.29–0.76
HBV viral load category (%)
<20 NA 11 (12.2) 
20–19 999 NA 40 (44.4) 
20 000 NA 39 (43.3) 
HBV, hepatitis B virus; IQR, interquartile range; ALT, alanine aminotransferase; APRI, apatients in Switzerland, in whom the prevalence was 10.8%
(Figure 1). Based on the lower APRI cut-off for cirrhosis (APRI >1.0),
cirrhosis could be excluded in over 90% of HIV monoinfected
patients, as well as in 84.4% and 76.3% of HIV/HBV co-infected
patients in Zambia and Switzerland, respectively.
3.3. Determinants of signiﬁcant liver ﬁbrosis
In adjusted analyses, HBsAg-positive patients were approxi-
mately three times more likely to have signiﬁcant liver ﬁbrosis
compared to HBsAg-negative individuals (adjusted odds ratio
(aOR) 2.75, 95% conﬁdence interval (CI) 1.61–4.74; Table 2). TheSwitzerland
p-Value HIV
(n = 1965)
HIV/HBV
(n = 93)
p-Value
0.07 447 (22.8) 21 (22.6) 0.97
0.99 306 (15.6) 25 (26.9) 0.004
0.30 39 (32–46) 38 (31–45) 0.38
0.20 191 (10.7) 12 (14.6) 0.26
0.32 216 (11.0) 8 (8.6) 0.47
0.59 277 (178–381) 293 (170–413) 0.64
0.72 76 (66–87) 75 (64–88) 0.84
0.35 205 (168–252) 199 (165–242) 0.41
0.02 215 (10.9) 23 (24.7) <0.001
) 0.01 0.39 (0.29–0.59) 0.50 (0.37–0.89) <0.001
NA NA 12 (16.2) NA
NA NA 29 (39.2) NA
NA NA 33 (44.6) NA
spartate aminotransferase-to-platelet-ratio index; NA, not applicable.
Table 2
Risk factors for signiﬁcant liver ﬁbrosis
No. (%) with signiﬁcant ﬁbrosis Univariable analysis (95% CI) Multivariable analysis (95% CI)
HBV co-infection
No
Yes
110 (4.2)
23 (12.2)
1
3.15 (1.95–5.06)
1
2.75 (1.61–4.74)
Sex
Female
Male
12 (1.4)
121 (6.3)
1
4.68 (2.57–8.51)
1
4.38 (2.30–8.32)
Age, years
16–40
>40
65 (3.9)
68 (6.0)
1
1.57 (1.11–2.23)
1
1.54 (1.05–2.25)
At-risk alcohol intake
No
Yes
93 (4.2)
30 (7.8)
1
1.93 (1.26–2.95)
1
1.55 (0.98–2.44)
Advanced HIV disease
No
Yes
95 (4.3)
38 (6.9)
1
1.67 (1.13–2.47)
1
1.48 (0.92–2.38)
CD4+ count, cells/ml
200
<200
75 (4.0)
58 (6.2)
1
1.56 (1.10–2.21)
1
1.40 (0.94–2.08)
Country
Zambia
Switzerland
33 (4.5)
100 (4.9)
1
1.09 (0.73–1.63)
1
1.10 (0.66–1.81)
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(3.25, 95% CI 1.44–7.33 in Zambia and 2.50, 95% CI 1.19–5.25 in
Switzerland; Figure 2). Male sex was another strong predictor of
signiﬁcant liver ﬁbrosis in pooled (OR 4.38, 95% CI 2.30–8.32) and
stratiﬁed analyses (3.87, 95% CI 1.49–10.08 in Zambia and 4.94,
95% CI 1.98–12.28 in Switzerland). Associations with age above
40 years, at-risk alcohol intake, advanced HIV disease, and a CD4
count <200 cells/ml were weaker and further attenuated on
multivariable analysis (Table 2). At-risk alcohol consumption
predicted signiﬁcant liver ﬁbrosis in Switzerland (OR 1.78, 95% CI
1.01–3.08), but not in Zambia (OR 1.34, 95% CI 0.62–2.90). The
results of the analysis in the SHCS after the exclusion of patients of
African origin (n = 331) remained similar, including the association
between HBV and liver ﬁbrosis (OR 2.64, 95% CI 1.20–5.82).
3.4. HBV viral load and liver ﬁbrosis
Of 96 HIV/HBV co-infected individuals in Zambia, 90 (94%) had
an available HBV viral load before the initiation of ART and the
median HBV viral load was 1186 (interquartile range (IQR) 53–
1.94e+06) IU/ml. Among the 93 HIV/HBV co-infected individuals in
Switzerland, 74 (80.0%) had an available measurement and the
median HBV viral load was 7299 (90–1.62e+08) IU/ml (p-value forFigure 2. Risk factors for signiﬁcant liver ﬁbrosis (APRI the comparison between the two countries = 0.07). A similar
proportion of HIV/HBV co-infected patients had a high baseline
HBV viral load (20 000 IU/ml) in both countries: 43.3% in Zambia
and 44.6% in Switzerland (Table 1). The proportion of patients with
signiﬁcant liver ﬁbrosis increased with HBV viral load: from 3.7% in
HBsAg-negative or HBsAg-positive with HBV viral load <20 IU/ml
to 12.8% in those with an HBV viral load 20 000 IU/ml in Zambia,
and from 4.4% to 21.2% in Switzerland (Figure 3). In multivariable
analyses, individuals with a high HBV viral load were more likely to
have signiﬁcant liver ﬁbrosis compared to HBsAg-negative or
HBsAg-positive patients with an undetectable HBV viral load: aOR
3.85 (95% CI 1.29–11.44) in Zambia and aOR 4.20 (95% CI 1.64–
10.76) in Switzerland (Supplementary Material, Table S1). Of
note, there was no clear difference in the proportion of patients
with signiﬁcant liver ﬁbrosis between HIV/HBV co-infected
patients with moderate and those with high viral loads in Zambia
(Figure 3). Among patients with high HBV viral loads, 72% in
Zambia and 58% in Switzerland had normal aminotransferases and
only one of these 47 patients had signiﬁcant ﬁbrosis. After
exclusion of these potentially immune-tolerant patients, the
proportion of individuals with signiﬁcant ﬁbrosis among those
with high viral loads increased from 13% to 36% in Zambia and from
21% to 50% in Switzerland.1.5) from multivariable logistic regression, by cohort.
Figure 3. Proportion of patients with signiﬁcant ﬁbrosis, by country and HBV
replication status.
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In this cross-sectional study of HIV-infected, ART-naı¨ve adults
in Zambia and Switzerland, it was found that HBV co-infection was
strongly associated with liver ﬁbrosis. HIV/HBV co-infected
patients were at least three times more likely to have signiﬁcant
ﬁbrosis compared to HIV monoinfected individuals. This associa-
tion was similar in Zambia and Switzerland despite differences in
the natural history of HBV infection and the genetic background of
the study populations, and seemed to be driven by HBV viral load.
Liver cirrhosis was rare in Zambia but present in over 10% of HIV/
HBV co-infected individuals in Switzerland. This analysis also
showed differences in alcohol intake and the impact on liver
disease between the two regions, underlining the need to better
characterize alcohol consumption and its health-related effects in
Sub-Saharan Africa.
Few studies have evaluated the impact of HBV co-infection on
the development of liver ﬁbrosis in HIV-infected individuals using
non-invasive methods. The Multicenter AIDS Cohort Study (MACS)
showed a strong association between viral hepatitis co-infection
and signiﬁcant liver ﬁbrosis using the APRI score, but the number
of HBV-infected patients analyzed was small.19 In SSA, two studies
based on transient elastography measurements showed conﬂicting
results: Hawkins et al. reported a strong association between HBV
co-infection and liver ﬁbrosis in HIV-infected individuals in
Nigeria, whereas Stabinski et al. found no such association in a
large cohort in Uganda.4,23 The present analysis of two large HIV
cohorts provides further evidence in favour of a link between HBV
co-infection and the development of liver ﬁbrosis. Although non-
invasive markers of liver ﬁbrosis have mostly been validated and
used in studies on HCV infection, they will increasingly be used in
the management of HBV infection, especially in the context of
improving coverage of ART in resource-limited settings. Recently,
Stockdale et al. showed that the APRI score had a good negative
predictive value for excluding cirrhosis and signiﬁcant ﬁbrosis
among HIV/HBV co-infected individuals in West Africa, but had a
poor overall diagnostic performance.24 As APRI is now recom-
mended by the WHO to evaluate treatment eligibility for chronic
HBV infection in the absence of liver biopsy or transient
elastography,13,14,25 there is an urgent need for validation studies
of this marker in other contexts, ideally in comparison with the
results of liver biopsies.
The association between HBV infection and liver ﬁbrosis was
found to depend on the level of HBV viral replication. In both
countries, the proportion of patients with signiﬁcant liver ﬁbrosis
was similar in HBV-uninfected and HBV co-infected patients with aviral load <20 IU/ml, whereas the prevalence of liver disease was
much higher in those with high viral loads. These results are in line
with those of prospective studies on viral replication in HBV
monoinfected individuals and the risk of liver cirrhosis and
HCC.26,27 HBV replication is inﬂuenced by the natural history of
HBV infection: patients infected during early childhood are likely
to undergo hepatitis B e antigen (HBeAg) seroconversion early in
life and to remain in a non-replicating phase for many years,
whereas those acquiring chronic HBV infection in adulthood often
experience high-level replication, hepatic inﬂammation, and
progressive development of liver ﬁbrosis.5 Compared to HIV/
HBV co-infected patients in Switzerland, liver cirrhosis was less
common among Zambians, despite what were likely longer
durations of HBV infection and similar HBV viral loads at ART
initiation. Host genetic factors could partially explain the lower
prevalence of cirrhosis in Zambia, analogous to the protective
effect of black ethnicity on the development of HCV-related
complications.28 Other potential explanations include differences
in viral factors (HBV genotypes and HBeAg positivity), as well as
environmental factors unaccounted for in the present analyses. For
instance, insulin resistance, a known risk factor for the develop-
ment of liver ﬁbrosis and HCC, might have been more prevalent in
the Swiss population.29 Although the results of this study conﬁrm
previous evidence on the impact of replicating HBV infection on
liver disease in treatment-naı¨ve populations, it is not yet known to
what extent HBV-active therapy reduces the excess liver-related
morbidity seen in HIV/HBV co-infected patients.
Another important difference between patients in Zambia and
Switzerland was the difference in the association between alcohol
consumption and liver disease. At-risk alcohol consumption did
not seem to be a strong risk factor for hepatic damage in Zambia,
whereas there was a clear association with signiﬁcant liver ﬁbrosis
in Switzerland. Due to the paucity of data published on alcohol
consumption and related health consequences in HIV-infected
individuals in SSA, it was difﬁcult to evaluate the generalizability
and robustness of these data. However, besides the potential
explanations mentioned above, the nature of the alcohol assess-
ment could have inﬂuenced the results. Self-reported alcohol
intake is subject to several biases and socio-cultural differences
between the two settings studied, making the comparison difﬁcult.
More research on alcohol-related and metabolic-induced liver
complications is urgently needed to improve our understanding of
liver disease progression in SSA, especially in HIV-infected
populations, in which alcohol consumption is high.
This assessment of liver-related complications using detailed
assessments of HBV virological determinants as well as other risk
factors for liver disease, including alcohol consumption and HIV
stage of disease, is a unique strength of this study. The impact of
HCV co-infection on liver ﬁbrosis could be excluded, as all patients
were tested for HCV infection, including in the Zambian cohort. The
association between HBV replication and liver ﬁbrosis could be
tested, as viral load measurements were available for >80% of the
HBV co-infected participants. However, due to missing HBeAg data
in a large sample of the patients, the inﬂuence of HBeAg positivity
could not be evaluated. As the majority of adult patients with HBV
infection in SSA are HBeAg-negative, these data could have
explained the differences in the prevalence of liver cirrhosis
between the two settings. Similarly, data on hepatitis delta
infection, a well-known risk factor for liver ﬁbrosis in HIV/HBV co-
infected individuals, were not available. Another limitation of this
study was the reliance on the APRI score to measure liver ﬁbrosis
and cirrhosis. As this test has not been properly validated in HBV-
infected populations in SSA, cut-offs generally used for HCV
infection had to be applied. Although this score has a good negative
predictive value to rule out liver cirrhosis (APRI <1.0), more data
are needed from SSA to better deﬁne its accuracy, and results need
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expand the results of this study, similar comparative analyses
should be repeated in cohorts with access to more detailed data on
liver-related events, including HCC and liver decompensation.
Finally, it was not possible to determine when the co-infected
participants acquired their HBV infection. Although it was
assumed that most patients in Zambia were infected during early
childhood and most in Switzerland during adulthood, individual-
level data on the time of infection would have allowed the role of
duration of infection to be better deﬁned.
In conclusion, as HBV-active antiretroviral agents such as
tenofovir become increasingly available, it is essential to improve
our knowledge on the prevalence and main determinants of liver
disease among those infected with HIV. These results show that the
prevalence and determinants of HBV-related liver ﬁbrosis in
Zambia and Switzerland are largely comparable. Further research
is needed to better understand the complex relationship between
the duration of HBV infection, natural history, viral replication, and
liver disease in different parts of the world.
Acknowledgements
We thank all the patients, doctors, and nurses associated with
the Centre for Infectious Disease Research in Zambia, Lusaka,
Zambia and the Swiss HIV Cohort Study (SHCS). The members of the
Swiss HIV Cohort Study are: Aubert V, Battegay M, Bernasconi E,
Bo¨ni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M,
Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H (Chairman of
the Clinical and Laboratory Committee), Fux CA, Gorgievski M,
Gu¨nthard H (President of the SHCS), Haerry D (deputy of ‘Positive
Council’), Hasse B, Hirsch HH, Hoffmann M, Ho¨sli I, Kahlert C, Kaiser
L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti
G, Martinez de Tejada B, Metzner K, Mu¨ller N, Nadal D, Nicca D,
Pantaleo G, Rauch A (Chairman of the Scientiﬁc Board), Regenass S,
Rickenbach M (Head of Data Centre), Rudin C (Chairman of the
Mother and Child Substudy), Scho¨ni-Affolter F, Schmid P, Schu¨p-
bach J, Speck R, Tarr P, Trkola A, Vernazza P, Weber R, Yerly S.
Funding/support: This study was supported by the Swiss
National Science Foundation (SNF grant number 148522, SHCS
project number 592) within the framework of the SHCS. The
Zambian cohort was supported by the National Institutes of Health
(IeDEA-Southern Africa, grant U01AI069924). G.W. was supported
by an Ambizione-PROSPER fellowship from the Swiss National
Science Foundation (PZ00P3_154730). M.J.V. was supported by the
Fogarty International Center of the National Institutes of Health
(K01TW009998). The funders had no role in the study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
Conﬂict of interest: All authors have completed and submitted
the ICMJE Form for Disclosure of Potential Conﬂicts of Interest. No
other disclosures are reported.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ijid.2016.08.028.
References
1. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-
related deaths in persons infected with the human immunodeﬁciency virus: the
D:A:D study. Arch Intern Med 2006;166:1632–41.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of
hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver
cancer worldwide. J Hepatol 2006;45:529–38.3. Thio CL, Seaberg EC, Skolasky Jr R, Phair J, Visscher B, Munoz A, et al. HIV-1,
hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort
Study (MACS). Lancet 2002;360:1921–6.
4. Hawkins C, Agbaji O, Ugoagwu P, Thio CL, Auwal M, Ani C, et al. Assessment of
liver ﬁbrosis by transient elastography in patients with HIV and hepatitis B
virus (HBV) co-infection in Nigeria. Clin Infect Dis 2013;57:e189–92.
5. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special
emphasis on disease progression and prognostic factors. J Hepatol
2008;48:335–52.
6. Martinson FE, Weigle KA, Royce RA, Weber DJ, Suchindran CM, Lemon SM. Risk
factors for horizontal transmission of hepatitis B virus in a rural district in
Ghana. Am J Epidemiol 1998;147:478–87.
7. Honge BL, Jespersen S, Medina C, Te Dda S, da Silva ZJ, Lewin S, et al. Hepatitis B
and delta virus are prevalent but often subclinical co-infections among HIV
infected patients in Guinea-Bissau, West Africa: a cross-sectional study. PLoS
One 2014;9:e99971.
8. Berhe N, Myrvang B, Gundersen SG. Intensity of Schistosoma mansoni, hepatitis
B, age, and sex predict levels of hepatic periportal thickening/ﬁbrosis (PPT/F): a
large-scale community-based study in Ethiopia. Am J Trop Med Hyg
2007;77:1079–86.
9. Kuniholm MH, Lesi OA, Mendy M, Akano AO, Sam O, Hall AJ, et al. Aﬂatoxin
exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West
Africa. Environ Health Perspect 2008;116:1553–7.
10. Bottero J, Lacombe K, Guechot J, Serfaty L, Miailhes P, Bonnard P, et al. Perfor-
mance of 11 biomarkers for liver ﬁbrosis assessment in HIV/HBV co-infected
patients. J Hepatol 2009;50:1074–83.
11. DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Lo Re 3rd V. Prevalence and
risk factors for signiﬁcant liver ﬁbrosis among HIV-monoinfected patients. BMC
Infect Dis 2010;10:116.
12. Vinikoor MJ, Sinkala E, Mweemba A, Zanolini A, Mulenga L, Sikazwe I, et al.
Elevated AST-to-platelet ratio index is associated with increased all-cause
mortality among HIV-infected adults in Zambia. Liver Int 2015;35:1886–92.
13. World Health Organization. Guidelines for the screening care and treatment of
persons with hepatitis C infection. Geneva: WHO; 2014.
14. World Health Organization. Guidelines for the prevention care and treatment of
persons with chronic hepatitis B infection. Geneva: WHO; 2015.
15. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of
antiretroviral therapy at primary care sites in Zambia: feasibility and early
outcomes. JAMA 2006;296:782–93.
16. Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P, et al.
Cohort proﬁle: the International epidemiological Databases to Evaluate AIDS
(IeDEA) in Sub-Saharan Africa. Int J Epidemiol 2012;41:1256–64.
17. Swiss HIV Cohort Study, Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin
C, Gu¨nthard HF, et al. Cohort proﬁle: the Swiss HIV Cohort Study. Int J Epidemiol
2010;39:1179–89.
18. Wai CT, Greenson JK, Fontana RJ, Kalbﬂeisch JD, Marrero JA, Conjeevaram HS,
et al. A simple noninvasive index can predict both signiﬁcant ﬁbrosis and
cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–26.
19. Price JC, Seaberg EC, Badri S, Witt MD, D’Acunto K, Thio CL. HIV monoinfection is
associated with increased aspartate aminotransferase-to-platelet ratio index, a
surrogate marker for hepatic ﬁbrosis. J Infect Dis 2012;205:1005–13.
20. AIDS Clinical Trials Group. Division of AIDS table for grading the severity of
adult and pediatric adverse events. Rockville MD: National Institutes of Health
National Institute of Allergy and Infectious Diseases Division of AIDS; 2004.
21. Conen A, Wang Q, Glass TR, Fux CA, Thurnheer MC, Orasch C, et al. Association of
alcohol consumption and HIV surrogate markers in participants of the Swiss
HIV Cohort Study. J Acquir Immune Deﬁc Syndr 2013;64:472–8.
22. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol
consumption questions (AUDIT-C): an effective brief screening test for problem
drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use
Disorders Identiﬁcation Test. Arch Intern Med 1998;158:1789–95.
23. Stabinski L, Reynolds SJ, Ocama P, Laeyendecker O, Ndyanabo A, Kiggundu V,
et al. High prevalence of liver ﬁbrosis associated with HIV infection: a study in
rural Rakai. Uganda Antivir Ther 2011;16:405–11.
24. Stockdale AJ, Phillips RO, Geretti AM, Group HS. The gamma-glutamyl trans-
peptidase to platelet ratio (GPR) shows poor correlation with transient elasto-
graphy measurements of liver ﬁbrosis in HIV-positive patients with chronic
hepatitis B in West Africa. Response to: ‘‘The gamma-glutamyl transpeptidase
to platelet ratio (GPR) predicts signiﬁcant liver ﬁbrosis and cirrhosis in patients
with chronic HBV infection in West Africa’’ by Lemoine et al. Gut 2016;65:
882–4.
25. World Health, Organization. Consolidated guidelines on the use of antiretrovi-
ral drugs for treating and preventing HIV infection: recommendations for a
public health approach 2013, revision. Geneva: WHO; 2013, Available at:
http://www.who.int/hiv/pub/guidelines/arv2013/en/. (accessed 31.05.2016)
26. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular
carcinoma across a biological gradient of serum hepatitis B virus DNA level.
JAMA 2006;295:65–73.
27. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on
the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678–86.
28. El-Serag HB, Kramer J, Duan Z, Kanwal F. Racial differences in the progression to
cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastro-
enterol 2014;109:1427–35.
29. Farrell G. Insulin resistance, obesity, and liver cancer. Clin Gastroenterol Hepatol
2014;12:117–9.
